Tizanidine Tablet
Product Images NDC 55111-180

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 55111-180). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddy's Laboratories Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container1 (Container1)

Tizanidine Tablets USP 2 mg oral tablets label. The label indicates a package of 150 tablets, prescription only. It states the active ingredient as tizanidine hydrochloride USP equivalent to 2 mg tizanidine base per tablet. Manufacturer is Dr. Reddy's Laboratories Limited, Bachupally, India. The label includes storage instructions and a barcode.*

FDA Label Image

Container2 (Container2)

Label for Tizanidine Tablets USP 2 mg oral tablets, prescription drug by Dr. Reddy's Laboratories Limited. The label indicates a package of 150 tablets. It includes the NDC 55111-179-15 and states that tablets are not interchangeable with Tizanidine capsules. The label also provides storage instructions and warnings to keep out of reach of children.*

FDA Label Image

Container3 (Container3)

Packaging label for Tizanidine Tablets USP 4 mg, oral tablets supplied by Dr. Reddy's Laboratories Limited. The bottle contains 150 tablets. The label states the tablets are Rx only and includes warnings about interchangeability with Tizanidine Capsules. It also has storage instructions, ingredient information, and a barcode.*

FDA Label Image

Container4 (Container4)

Label for Tizanidine Tablets USP 4 mg oral tablets by Dr. Reddy's Laboratories Limited. The label states the product contains 150 tablets and includes the NDC number 55111-180-15. It notes that Tizanidine tablets are not interchangeable with Tizanidine capsules and provides storage instructions.*

FDA Label Image

Fig1 (Fig1)

A line graph showing plasma Tizanidine concentration (ng/mL) over time (hours) following dosing. It compares 2x 4 mg Tizanidine tablets and capsules taken with and without food, illustrating how food intake affects the drug concentration profile within 24 hours after dosing.*

FDA Label Image

Fig2 (Fig2)

A line graph showing improvement in Ashworth Score over time (hours post-dose) for three groups: placebo, 8 mg tizanidine, and 16 mg tizanidine. The graph depicts improvement trends with error bars, highlighting the higher doses of tizanidine yielding greater improvement compared to placebo.*

FDA Label Image

Fig3 (Fig3)

A line chart comparing improvement in Ashworth scores over three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). Data show higher improvement for tizanidine (mean dose 28.8 mg) compared to placebo, with error bars representing variability.*

FDA Label Image

Structure (Structure)

Chemical structure of Tizanidine hydrochloride, showing a fused bicyclic ring system with attached nitrogen atoms and a chlorine substituent. The diagram depicts the molecular framework relevant to the active ingredient in the Tizanidine tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.